Where do oral and topical JAK inhibitors fit into your treatment algorithm and approach to atopic dermatitis?  

When considering systemic treatment for dermatitis, I perform extended patch testing based upon patient's history of cutaneous contactants. This identifies patients with dermatitis that can often be cured by avoiding cutaneous and systemic (i.e. ingestion) exposure to identified allergens. Patients...

Currently, it is challenging to use the JAK inhibitors for atopic dermatitis given the black box warning, which I share with all parents before prescribing. I will use topical ruxolitinib as a steroid-sparing agent if the patient fails calcineurin inhibitors and Eucrisa as these have a more proven t...